Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.

Publication ,  Journal Article
Ashley, DM; Riffkin, CD; Lovric, MM; Mikeska, T; Dobrovic, A; Maxwell, JA; Friedman, HS; Drummond, KJ; Kaye, AH; Gan, HK; Johns, TG; Hawkins, CJ
Published in: Br J Cancer
July 22, 2008

TRAIL/Apo-2L has shown promise as an anti-glioma drug, based on investigations of TRAIL sensitivity in established glioma cell lines, but it is not known how accurately TRAIL signalling pathways of glioma cells in vivo are reproduced in these cell lines in vitro. To replicate as closely as possible the in vivo behaviour of malignant glioma cells, 17 early passage glioma cell lines and 5 freshly resected gliomas were exposed to TRAIL-based agents and/or chemotherapeutic drugs. Normal human hepatocytes and astrocytes and established glioma cell lines were also tested. Cross-linked TRAIL, but not soluble TRAIL, killed both normal cell types and cells from three tumours. Cells from only one glioma were killed by soluble TRAIL, although only inefficiently. High concentrations of cisplatin were lethal to glioma cells, hepatocytes and astrocytes. Isolated combinations of TRAIL and chemotherapy drugs were more toxic to particular gliomas than normal cells, but no combination was generally selective for glioma cells. This study highlights the widespread resistance of glioma cells to TRAIL-based agents, but suggests that a minority of high-grade glioma patients may benefit from particular combinations of TRAIL and chemotherapy drugs. In vitro sensitivity assays may help identify effective drug combinations for individual glioma patients.

Duke Scholars

Published In

Br J Cancer

DOI

EISSN

1532-1827

Publication Date

July 22, 2008

Volume

99

Issue

2

Start / End Page

294 / 304

Location

England

Related Subject Headings

  • Vincristine
  • Tumor Necrosis Factor-alpha
  • Temozolomide
  • TNF-Related Apoptosis-Inducing Ligand
  • Recombinant Fusion Proteins
  • Procarbazine
  • Oncology & Carcinogenesis
  • Middle Aged
  • Membrane Glycoproteins
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ashley, D. M., Riffkin, C. D., Lovric, M. M., Mikeska, T., Dobrovic, A., Maxwell, J. A., … Hawkins, C. J. (2008). In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer, 99(2), 294–304. https://doi.org/10.1038/sj.bjc.6604459
Ashley, D. M., C. D. Riffkin, M. M. Lovric, T. Mikeska, A. Dobrovic, J. A. Maxwell, H. S. Friedman, et al. “In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.Br J Cancer 99, no. 2 (July 22, 2008): 294–304. https://doi.org/10.1038/sj.bjc.6604459.
Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, et al. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer. 2008 Jul 22;99(2):294–304.
Ashley, D. M., et al. “In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.Br J Cancer, vol. 99, no. 2, July 2008, pp. 294–304. Pubmed, doi:10.1038/sj.bjc.6604459.
Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, Friedman HS, Drummond KJ, Kaye AH, Gan HK, Johns TG, Hawkins CJ. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer. 2008 Jul 22;99(2):294–304.

Published In

Br J Cancer

DOI

EISSN

1532-1827

Publication Date

July 22, 2008

Volume

99

Issue

2

Start / End Page

294 / 304

Location

England

Related Subject Headings

  • Vincristine
  • Tumor Necrosis Factor-alpha
  • Temozolomide
  • TNF-Related Apoptosis-Inducing Ligand
  • Recombinant Fusion Proteins
  • Procarbazine
  • Oncology & Carcinogenesis
  • Middle Aged
  • Membrane Glycoproteins
  • Male